A Phase 2 interventional study of MK-6194 and Placebo in Non-segmental Vitiligo, sponsored by Merck Sharp & Dohme LLC. Terminated at 68 sites in 18 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Vitiligo with a site in United States — 14 open to participants now, 24 under way, 7 of them phase 3. Vitiligo · United States.
Among the 80 studies in Vitiligo with a site in United States, this one is the 19th largest by enrollment of the 68 interventional ones that give a count, is one of 10 that started in 2023, is one of 31 in phase 2, and was the 63rd registered.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
Browse Vitiligo studies →14 of the 80 studies in Vitiligo with a site in United States are open now. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United States, Poland
Ages 18–65
CorEvitas · Sites in United States
Ages 12+ · Healthy volunteers
Eli Lilly and Company · Sites in United States, Belgium, Canada and 2 more countries
Ages 18–75
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 9 more countries
Ages 18–99
Elixiron Immunotherapeutics (Hong Kong) Ltd. · Sites in United States, Taiwan
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 33 · Phase 3 14 · Phase 4 1
First in 1995; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 169 is above the median of 36 across 265 interventional studies indexed under Vitiligo.
Median enrollment 37 across the 68 interventional studies, 1,750 across the 12 observational. Of the 50 that completed or were terminated, 25 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 80 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 1 study filed under Vitiligo — fewer than ten, so there is no comparison to draw.
8 of the studies in Vitiligo with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06163326Phase 3PfizerA 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo | 2027-03-31 |
| NCT06072183Phase 3PfizerA 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 | 2027-07-30 |
| NCT03577327Northwestern UniversityThe Gut and Skin Microbiome in Vitiligo Disease Progression | 2026-12 |
| NCT07223229Elixiron Immunotherapeutics (Hong Kong) Ltd.Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients | 2026-12-31 |
| NCT07108283TakedaA Study of Zasocitinib in Adults With Nonsegmental Vitiligo | 2027-03-26 |
Add all 8 to your calendar (.ics) → With an account.
Among the 80 studies in Vitiligo with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-6194 and how well people tolerate it. Researchers also want to learn if people who take MK-6194 have more of a decrease in the amount of vitiligo on their face compared to people who take placebo.
This study will consist of two periods. During the Double-Blind Treatment Period, participants will be randomized to one of three treatment arms to receive MK-6194 at one of two doses or placebo and will be evaluated for safety and efficacy. Participants who complete this period may enter the Blinded Extension Period, during which MK-6194 treatment will continue or placebo recipients will be re-randomized to MK-6194 at one of two doses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive subcutaneous (SC) MK-6194 3 mg every two weeks (Q2W).
Biological: MK-6194
Participants will receive SC MK-6194 3 mg every four weeks (Q4W).
Biological: MK-6194
Participants will receive SC Placebo Q2W.
Drug: Placebo
After completing 24 weeks of treatment with SC MK-6194 administered 3 mg Q2W in the Double-Blind Treatment Period, participants will continue to receive SC MK-6194 3 mg Q2W in the Blinded Extension Period.
Biological: MK-6194
After completing 24 weeks of treatment with SC MK-6194 administered 3 mg Q4W in the Double-Blind Treatment Period, participants will continue to receive SC MK-6194 3 mg Q4W in the Blinded Extension Period.
Biological: MK-6194
After completing 24 weeks of treatment with SC Placebo administered Q2W in the Double-Blind Treatment Period, participants will be re-randomized to receive SC MK-6194 3 mg Q2W in the Blinded Extension Period.
Biological: MK-6194
After completing 24 weeks of treatment with SC Placebo administered Q2W in the Double-Blind Treatment Period, participants will be re-randomized to receive SC MK-6194 3 mg Q4W in the Blinded Extension Period.
Biological: MK-6194
MK-6194 administered subcutaneously (SC)
Placebo comparator to MK-6194 administered SC
Percent Change From Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24
VASI is a validated scoring method that measures the extent and severity of vitiligo depigmentation. The F-VASI measures vitiligo involvement of the facial area. For facial lesions, size is estimated using fingertip units (FTU), fingers, or thumbs: 1 FTU is approximately 0.03% body surface area (BSA), while a finger or thumb is approximately 0.1% BSA. Depigmentation at each site is graded to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. F-VASI is calculated by multiplying the area (in FTUs) by the depigmentation percentage for each facial site and summing the values. Scores range from 0 to approximately 3.5, with higher scores indicating greater vitiligo involvement of the facial area (more severe depigmentation). Percent change from baseline calculated as post-baseline value minus baseline value, divided by baseline value and multiplied by 100%. Longitudinal data analysis (LDA) model-based least squares mean (LSM) percent change from baseline to Week 24 was reported.
Time frame: Baseline and Week 24
Number of Participants Who Experienced an Adverse Event (AE)
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention whether or not considered related to the study intervention. The number of participants who experienced an AE is reported.
Time frame: Up to approximately 28 weeks
Number of Participants Who Discontinued Study Treatment Due to an AE
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported here.
Time frame: Up to approximately 24 weeks
Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24
T-VASI is a validated scoring method that measures the extent and severity of vitiligo across the entire body. The body is divided into six regions: head/neck, hands, upper extremities, trunk, lower extremities, and feet. One hand unit (palm and fingers together) represents 1% of BSA. Depigmentation for each region is graded to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. For regions with multiple lesions, percentages are averaged. The T-VASI score is calculated by multiplying the area (in hand units) by the depigmentation percentage for each region and summing all regions. Scores range from 0 to 100, with 0 indicating no vitiligo and 100 indicating complete body involvement. Percent change from baseline calculated as post-baseline value minus baseline value, divided by baseline value and multiplied by 100%. LDA model-based LSM percent change from baseline to Week 24 was reported.
Time frame: Baseline and Week 24
| Milestone | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | MK-6194 3 mg Q2W (Double-blind) / MK-6194 3 mg Q2W (Extension) | MK-6194 3 mg Q4W (Double-blind) / MK-6194 3 mg Q4W (Extension) | Placebo (Double-blind)/ MK-6194 3 mg Q2W (Extension) | Placebo (Double-blind)/ MK-6194 3 mg Q4W (Extension) |
|---|---|---|---|---|---|---|---|
| Started | 57 | 55 | 57 | 0 | 0 | 0 | 0 |
| Completed | 34 | 45 | 53 | 0 | 0 | 0 | 0 |
| Not completed | 23 | 10 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 4 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 12 | 4 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 6 | 3 | 0 | 0 | 0 | 0 | 0 |
| Milestone | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | MK-6194 3 mg Q2W (Double-blind) / MK-6194 3 mg Q2W (Extension) | MK-6194 3 mg Q4W (Double-blind) / MK-6194 3 mg Q4W (Extension) | Placebo (Double-blind)/ MK-6194 3 mg Q2W (Extension) | Placebo (Double-blind)/ MK-6194 3 mg Q4W (Extension) |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 34 | 43 | 27 | 26 |
| Completed | 0 | 0 | 0 | 17 | 25 | 13 | 16 |
| Not completed | 0 | 0 | 0 | 17 | 18 | 14 | 10 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 2 | 0 | 1 | 0 |
| Withdrew: Site terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 12 | 12 | 7 | 7 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 | 3 | 4 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
VASI is a validated scoring method that measures the extent and severity of vitiligo depigmentation. The F-VASI measures vitiligo involvement of the facial area. For facial lesions, size is estimated using fingertip units (FTU), fingers, or thumbs: 1 FTU is approximately 0.03% body surface area (BSA), while a finger or thumb is approximately 0.1% BSA. Depigmentation at each site is graded to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. F-VASI is calculated by multiplying the area (in FTUs) by the depigmentation percentage for each facial site and summing the values. Scores range from 0 to approximately 3.5, with higher scores indicating greater vitiligo involvement of the facial area (more severe depigmentation). Percent change from baseline calculated as post-baseline value minus baseline value, divided by baseline value and multiplied by 100%. Longitudinal data analysis (LDA) model-based least squares mean (LSM) percent change from baseline to Week 24 was reported.
| Percent change | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24 | -4.55 (-16.79 to 7.68) | -12.13 (-24.29 to 0.03) | -4.01 (-15.70 to 7.69) |
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention whether or not considered related to the study intervention. The number of participants who experienced an AE is reported.
| Participants | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 51 | 47 | 44 |
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported here.
| Participants | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE | 9 | 5 | 1 |
T-VASI is a validated scoring method that measures the extent and severity of vitiligo across the entire body. The body is divided into six regions: head/neck, hands, upper extremities, trunk, lower extremities, and feet. One hand unit (palm and fingers together) represents 1% of BSA. Depigmentation for each region is graded to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. For regions with multiple lesions, percentages are averaged. The T-VASI score is calculated by multiplying the area (in hand units) by the depigmentation percentage for each region and summing all regions. Scores range from 0 to 100, with 0 indicating no vitiligo and 100 indicating complete body involvement. Percent change from baseline calculated as post-baseline value minus baseline value, divided by baseline value and multiplied by 100%. LDA model-based LSM percent change from baseline to Week 24 was reported.
| Percent Change | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24 | -1.69 (-11.02 to 7.65) | -9.08 (-18.24 to 0.08) | 0.78 (-7.77 to 9.34) |
Collected over Up to approximately 61 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-6194 3 mg Q2W | 0/57 (0%) | 3/57 (5.3%) | 48/57 (84.2%) |
| MK-6194 3 mg Q4W | 0/55 (0%) | 3/55 (5.5%) | 43/55 (78.2%) |
| Placebo | 0/57 (0%) | 0/57 (0%) | 34/57 (59.6%) |
| MK-6194 3 mg Q2W (Double-blind) / MK-6194 3 mg Q2W (Extension) | 0/34 (0%) | 0/34 (0%) | 19/34 (55.9%) |
| MK-6194 3 mg Q4W (Double-blind) / MK-6194 3 mg Q4W (Extension) | 0/43 (0%) | 0/43 (0%) | 27/43 (62.8%) |
| Placebo (Double-blind) / MK-6194 3 mg Q2W (Extension) | 0/27 (0%) | 0/27 (0%) | 21/27 (77.8%) |
| Placebo (Double-blind) / MK-6194 3 mg Q4W (Extension) | 0/26 (0%) | 1/26 (3.8%) | 21/26 (80.8%) |
| Event | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | MK-6194 3 mg Q2W (Double-blind) / MK-6194 3 mg Q2W (Extension) | MK-6194 3 mg Q4W (Double-blind) / MK-6194 3 mg Q4W (Extension) | Placebo (Double-blind) / MK-6194 3 mg Q2W (Extension) | Placebo (Double-blind) / MK-6194 3 mg Q4W (Extension) |
|---|---|---|---|---|---|---|---|
| Cartilage injuryInjury, poisoning and procedural complications | 0/57 | 0/55 | 0/57 | 0/34 | 0/43 | 0/27 | 1/26 |
| DiarrhoeaGastrointestinal disorders | 0/57 | 1/55 | 0/57 | 0/34 | 0/43 | 0/27 | 0/26 |
| AppendicitisInfections and infestations | 0/57 | 1/55 | 0/57 | 0/34 | 0/43 | 0/27 | 0/26 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/57 | 1/55 | 0/57 | 0/34 | 0/43 | 0/27 | 0/26 |
| Injection site rashGeneral disorders | 1/57 | 0/55 | 0/57 | 0/34 | 0/43 | 0/27 | 0/26 |
| Hepatic enzyme increasedInvestigations | 1/57 | 0/55 | 0/57 | 0/34 | 0/43 | 0/27 | 0/26 |
| Rash papularSkin and subcutaneous tissue disorders | 1/57 | 0/55 | 0/57 | 0/34 | 0/43 | 0/27 | 0/26 |
| Event | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | MK-6194 3 mg Q2W (Double-blind) / MK-6194 3 mg Q2W (Extension) | MK-6194 3 mg Q4W (Double-blind) / MK-6194 3 mg Q4W (Extension) | Placebo (Double-blind) / MK-6194 3 mg Q2W (Extension) | Placebo (Double-blind) / MK-6194 3 mg Q4W (Extension) |
|---|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 18/57 | 12/55 | 1/57 | 8/34 | 8/43 | 4/27 | 12/26 |
| Injection site erythemaGeneral disorders | 19/57 | 23/55 | 1/57 | 5/34 | 13/43 | 2/27 | 6/26 |
| NasopharyngitisInfections and infestations | 5/57 | 1/55 | 13/57 | 0/34 | 5/43 | 3/27 | 1/26 |
| HeadacheNervous system disorders | 10/57 | 8/55 | 3/57 | 0/34 | 1/43 | 0/27 | 0/26 |
| Injection site pruritusGeneral disorders | 9/57 | 6/55 | 1/57 | 2/34 | 7/43 | 1/27 | 3/26 |
| PruritusSkin and subcutaneous tissue disorders | 5/57 | 2/55 | 2/57 | 1/34 | 3/43 | 4/27 | 1/26 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/57 | 4/55 | 4/57 | 1/34 | 2/43 | 0/27 | 0/26 |
| Injection site swellingGeneral disorders | 3/57 | 5/55 | 0/57 | 2/34 | 6/43 | 0/27 | 0/26 |
| Injection site painGeneral disorders | 2/57 | 7/55 | 2/57 | 0/34 | 3/43 | 0/27 | 1/26 |
| Eosinophil count increasedInvestigations | 7/57 | 4/55 | 0/57 | 2/34 | 4/43 | 1/27 | 1/26 |
| Age, Continuous(Years) | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | Total |
|---|---|---|---|---|
| Mean | 45.3 ± 12.1 | 49.9 ± 12.0 | 46.4 ± 14.6 | 47.2 ± 13.0 |
| Age, Customized(Participants) | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | Total |
|---|---|---|---|---|
| Adults (between 18 and 64 years) | 55 | 47 | 51 | 153 |
| From 65 to 84 years | 2 | 8 | 6 | 16 |
| Sex: Female, Male(Participants) | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | Total |
|---|---|---|---|---|
| Female | 35 | 27 | 30 | 92 |
| Male | 22 | 28 | 27 | 77 |
| Ethnicity (NIH/OMB)(Participants) | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 23 | 15 | 19 | 57 |
| Not Hispanic or Latino | 31 | 35 | 37 | 103 |
| Unknown or Not Reported | 3 | 5 | 1 | 9 |
| Race (NIH/OMB)(Participants) | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 6 | 5 | 3 | 14 |
| Asian | 8 | 7 | 8 | 23 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 7 | 2 | 12 |
| White | 34 | 34 | 40 | 108 |
| More than one race | 5 | 2 | 3 | 10 |
| Unknown or Not Reported | 1 | 0 | 1 | 2 |
| Vitiligo Status (Stable vs Active)(Participants) | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | Total |
|---|---|---|---|---|
| Stable | 29 | 28 | 30 | 87 |
| Active | 28 | 27 | 27 | 82 |
| Previous JAK Inhibitor Exposure (Yes vs. No)(Participants) | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | Total |
|---|---|---|---|---|
| Yes | 13 | 11 | 12 | 36 |
| No | 44 | 44 | 45 | 133 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Nov 2023 to primary completion in Mar 2025, 15 months.
Results were first posted in Mar 2026, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-6194